Connect with us

Corporate

Berlin Pharmaceutical and Acino Pharma Sign Partnership in Thailand

Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company’s products in Thailand

Published

on

Peter Burema, CEO of Acino Group

Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma AG (SIX: ACIN) signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company’s current and future products in Thailand.

“The new products will complement our current line of therapies as well as significantly expand our presence into new areas,” said Amal Naj, Chief Executive Officer of Berlin. “We are very excited about this association with Acino and the high quality products we will bring to our patients at affordable prices,” he said.

Peter Burema, CEO of Acino Group

Peter Burema, CEO of Acino Group

Peter Burema, CEO of Acino Group, said,

“We are very pleased to partner with one of the leading pharmaceutical companies in Thailand to introduce our products in the market. We see great opportunities for our products there and rest of Asia and other emerging markets.”

Acino, based in Basle, Switzerland, specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceutical companies throughout Europe

Mr. Naj said the vast majority of the Acino products Berlin will introduce in Thailand are for the treatment of urological disorders, cancer and pain. The company’s current products are prescribed mainly for the treatment of cardiovascular and metabolic diseases and gastro-intestinal disorders.

Mr. Naj said a number of Acino products are innovative, and they will help strengthen Berlin’s market presence in the highly competitive market.

Berlin currently manufactures most of its products in GMP-approved (Good Manufacturing Practice) and ISO-certified facilities, and imports active pharmaceutical ingredients (API) as well as finished products from Canada, France, and India.

Berlin is one of the top 10 pharmaceutical companies in Thailand and is a market leader in many of the products it markets. The company employs 550 people.

The Acino Group is headquartered in Basle, and currently employs approximately 380 staff. Acino Holding Ltd., the Group’s parent, is listed on the SIX Swiss Exchange (SIX: ACIN).

Please note that under Thai FDA regulation, we cannot discuss individual products.

CONTACT

Pajasalmi, Ruangkittikul & Associates Ltd.

Khun Panarasee Thaiwatcharamas

Khun Komson Kaemthong

+662 651 8989 Ext. 222 and 441

Berlin Pharmaceutical Industry

Amal Naj, CEO

+662 652 9590

amal@berlinpharm.com

Acino Pharma AG

Peter Burema, CEO

+41 61 338 60 00

info@acino-pharma.com

www.acino-pharma.com

SOURCE Berlin Pharmaceutical Industry

Back to top

RELATED LINKS

http://www.acino-pharma.com

via Berlin Pharmaceutical and Acino Pharma of Switzerland Sign Partnership Agreement to Market a… — BANGKOK, Sept. 5, 2011 /PRNewswire/ —.

Corporate

The environmental case for remote working

Anyone searching for a silver lining to the pandemic should look to the clear, blue skies above them. A reduction in pollution worldwide has been an unintended benefit of the lockdowns and stay-in-place orders imposed to control the spread of COVID-19.

Published

on

During the pandemic, the environmental and societal benefits of working at home quickly became apparent. How can businesses protect these benefits in the future?

(more…)
Continue Reading

Investment

Thailand Q1 Investment Applications Soar 80% as FDI More Than Double says BOI

The top three source countries of FDI applications during the first quarter were South Korea, China, and Singapore, with similar levels of investment. Korean investment soared due to a large-scale joint venture in the medical sector, Ms Duangjai said.

Published

on

The Thailand Board of Investment (BOI) said today that in the first quarter of 2021, investment applications rose 80% from the year earlier period to a total value of 123.4 billion baht (USD3.9 billion), led by projects in the medical and electric and electronics (E&E) sectors, as foreign direct investment (FDI) applications more than doubled.

(more…)
Continue Reading

Most Viewed

Subscribe via Email

Enter your email address to subscribe and receive notifications of new posts by email.

Join 14,162 other subscribers

Wise

Recent